Disposition and antimuscarinic effects of the urinary bladder spasmolytics propiverine: Influence of dosage forms and circadian-time rhythms

Journal of Clinical Pharmacology

Volumn 48, Issue 5, 2008, Pages 570-579

  May, Karen ^a   Westphal, Kristin ^a   Giessmann, Thomas ^a   Wegner, Danilo ^a   Adam, Ulrike ^a   Lerch, Markus M ^a   Oertel, Reinhard ^b   Warzok, Rolf W ^a   Weitschies, Werner ^a   Braeter, Manfred ^c,d   Siegmund, Werner ^a  

^a UNIVERSITY OF GREIFSWALD   (Germany)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^c APOGEPHA Arzneimittel GmbH   (Germany)

^d APOGEPHA ^*

Author keywords

ABCC2; Circadian rhythm; Extended release; Propiverine

Indexed keywords

CYTOCHROME P450 3A4; DRUG METABOLITE; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; PROPIVERINE;

ADULT; ANXIETY; AREA UNDER THE CURVE; ARTICLE; CIRCADIAN RHYTHM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG DOSAGE FORM COMPARISON; DRUG EFFECT; DRUG FORMULATION; DRUG HALF LIFE; DRUG SAFETY; DRUG URINE LEVEL; DRUG WITHDRAWAL; DYSPNEA; EDEMA; FEMALE; HEART PALPITATION; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PHOTOSENSITIVITY; PROTEIN EXPRESSION; PULSE RATE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TACHYCARDIA; VISUAL DISORDER; XEROSTOMIA;

ADMINISTRATION, ORAL; ADULT; AREA UNDER CURVE; BENZILATES; BIOLOGICAL AVAILABILITY; CAPSULES; CHOLINERGIC ANTAGONISTS; CIRCADIAN RHYTHM; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP3A; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; MUSCARINIC ANTAGONISTS; P-GLYCOPROTEIN; PARASYMPATHOLYTICS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; URINARY BLADDER;

EID: 41849117249     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270008315314     Document Type: Article

References (38)

1. Matsushima S., Inada H., Asai T., Naka M., Tanaka T. Propiverine hydrochloride, an anti-pollakiuric agent, inhibits the activity of actomyosin ATPase from the urinary bladder. Eur J Pharmacol. 1997 ; 333: 93-97.
2. Wuest M., Hecht J., Christ T., et al. Pharmacodynamics of propiverine and 3 of its main metabolites on detrusor contraction. Br J Pharmacol. 2005 ; 145: 608-619.
3. Wuest M., Weiss A., Waelbroeck M., et al. Propiverine and metabolites: differences in binding to muscarinic receptors and in functional models of detrusor contraction. Naunyn Schmiedebergs Arch Pharmacol. 2006 ; 374: 87-97.
4. Madersbacher H., Murtz G. Efficacy, tolerability, and safety profile of propiverine in the treatment of the overactive bladder (non-neurogenic and neurogenic). World J Urol. 2001 ; 19: 324-335.
5. Olsson B., Szamosi J. Multiple dose pharmacokinetics of a new once daily extended release tolterodine formulation versus immediate release tolterodine. Clin Pharmacokinet. 2001 ; 40: 227-235.
6. Siddiqui MA, Perry CM, Scott LJ Oxybutynin extended-release: a review of its use in the management of overactive bladder. Drugs. 2004 ; 64: 885-912.
7. Michel MC, Hegde SS Treatment of the overactive bladder syndrome with muscarinic receptor antagonists: a matter of metabolites ? Naunyn Schmiedebergs Arch Pharmacol. 2006 ; 374: 79-85.
8. Siepmann M., Nokhodian A., Thummler D., Kirch W. Pharmacokinetics and safety of propiverine in patients with fatty liver disease. Eur J Clin Pharmacol. 1998 ; 54: 767-771.
9. Wengler A., Schneider T., Zschiesche M., Siegmund W. Studies on the metabolism of the bladder spasmolytic, propiverin (mictonorm) in humans [in German]. Pharmazie. 1988 ; 43: 652-653.
10. Siegmund W., Nigussie M., Tilahun K., Aitenfissu H., Franke G., Wengler A. Anticholinergic properties of propiverine and its metabolites. Pharmazie. 1990 ; 45: 67-68.
11. Giessmann T., May K., Moritz KU, Oertel R., Kroemer HK, Siegmund W. Disposition of propiverine and its metabolites is influenced by MRP2. Naunyn Schmiedebergs Arch Pharmacol. 2004 ; 369: R156.
12. Chan LM, Lowes S., Hirst BH The ABCs of drug transport in intestine and liver: efflux proteins limiting drug absorption and bioavailability. Eur J Pharm Sci. 2004 ; 21: 25-51.
13. Dietrich CG, Geier A., Elferink Rpjo. ABC of oral bioavailability: transporters as gatekeepers in the gut. Gut. 2003 ; 52: 1788-1795.
14. Takano M., Yumoto R., Murakami T. Expression and function of efflux drug transporters in the intestine. Pharmacol Ther. 2006 ; 109: 137-161.
15. Mouly S., Paine MF P-glycoprotein increases from proximal to distal regions of human small intestine. Pharm Res. 2003 ; 20: 1595-1599.
16. Zimmermann C., Gutmann H., Hruz P., Gutzwiller JP, Beglinger C., Drewe J. Mapping of multidrug resistance gene 1 and multidrug resistance-associated protein isoform 1 to 5 mRNA expression along the human intestinal tract. Drug Metab Dispos. 2005 ; 33: 219-224.
17. Englund G., Rorsman F., Ronnblom S., et al. Regional levels of drug transporters along the human intestinal tract: co-expression of ABC and SLC transporters and comparison with Caco-2 cells. Eur J Pharm Sci. 2006 ; 29: 269-277.
18. Paine MF, Khalighi M., Fisher JM, et al. Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. J Pharmacol Exp Ther. 1997 ; 283: 1552-1562.
19. Nakamura T., Sakaeda T., Ohmoto N., et al. Real-time quantitative polymerase chain reaction for MDR1, MRP1, MRP2, and CYP3A-mRNA levels in Caco-2 cell lines, human duodenal enterocytes, normal colorectal tissues, and colorectal adenocarcinomas. Drug Metab Dispos. 2002 ; 30: 4-6.
20. May K., Giessmann T., Oertel R., Braeter M., Siegmund W. Release-rate dependent absorption of propiverine an example for regio-selective intestinal absorption. Basic Clin Pharmacol Toxicol. 2007 ; 101 (Suppl 1). 136.
21. Giessmann T., Modess C., Hecker U., et al. CYP2D6 genotype and induction of intestinal drug transporters by rifampin predict presystemic clearance of carvedilol in healthy subjects. Clin Pharmacol Ther. 2004 ; 75: 213-222.
22. Siegmund W., Ludwig K., Giessmann T., et al. The effects of the human MDR1 genotype on the expression of duodenal P-glycoprotein and disposition of the probe drug talinolol. Clin Pharmacol Ther. 2002 ; 72: 572-583.
23. Oertel R., Kilian B., Siegmund W., Kirch W. Determination of propiverine and its metabolites in rat samples by liquid chromatography-tandem mass spectrometry. J Chromatogr A. 2007 ; 1149: 121-126.
24. Richter K., Scheithauer S., Thummler D. High-performance liquid chromatographic determination of propiverine and its N-oxide in human serum. J Chromatogr B Biomed Sci Appl. 1998 ; 708: 325-329.
25. Gupta SK, Sathyan G. Pharmacokinetics of an oral once-a-day controlled-release oxybutynin formulation compared with immediate-release oxybutynin. J Clin Pharmacol. 1999 ; 39: 289-296.
26. Junemann KP, Hessdorfer E., Unamba-Oparah I., et al. Propiverine hydrochloride immediate and extended release: comparison of efficacy and tolerability in patients with overactive bladder. Urol Int. 2006 ; 77: 334-339.
27. Choi JS, Park HJ Circadian changes in pharmacokinetics of cyclosporin in healthy volunteers. Res Commun Mol Pathol Pharmacol. 1999 ; 103: 109-112.
28. English J., Dunne M., Marks V. Diurnal variation in prednisolone kinetics. Clin Pharmacol Ther. 1983 ; 33: 381-385.
29. Hla KK, Latham AN, Henry JA Influence of time of administration on verapamil pharmacokinetics. Clin Pharmacol Ther. 1992 ; 51: 366-370.
30. Min DI, Chen HY, Lee MK, Ashton K., Martin MF Time-dependent disposition of tacrolimus and its effect on endothelin-1 in liver allograft recipients. Pharmacotherapy. 1997 ; 17: 457-463.
31. Hoogerwerf WA Biologic clocks and the gut. Curr Gastroenterol Rep. 2006 ; 8: 353-359.
32. Keller J., Groger G., Cherian L., Gunther B., Layer P. Circadian coupling between pancreatic secretion and intestinal motility in humans. Am J Physiol Gastrointest Liver Physiol. 2001 ; 280: G273 - G278.
33. Levi F., Schibler U. Circadian rhythms: mechanisms and therapeutic implications. Annu Rev Pharmacol Toxicol. 2007 ; 47: 593-628.
34. Ohno M., Yamaguchi I., Ito T., Saiki K., Yamamoto I., Azuma J. Circadian variation of the urinary 6beta-hydroxycortisol to cortisol ratio that would reflect hepatic CYP3A activity. Eur J Clin Pharmacol. 2000 ; 55: 861-865.
35. Galteau MM, Shamsa F. Urinary 6beta-hydroxycortisol: a validated test for evaluating drug induction or drug inhibition mediated through CYP3A in humans and in animals. Eur J Clin Pharmacol. 2003 ; 59: 713-733.
36. Ando H., Yanagihara H., Sugimoto K., et al. Daily rhythms of P-glycoprotein expression in mice. Chronobiol Int. 2005 ; 22: 655-665.
37. Ichikawa M., Yoshimura A., Furukawa T., Sumizawa T., Akiyama S. Modulators of the multidrug-transporter, P-glycoprotein, exist in the human plasma. Biochem Biophys Res Commun. 1990 ; 166: 74-80.
38. Mulder HS, Pinedo HM, Timmer AT, Rao BR, Lankelma J. Multidrug resistance-modifying components in human plasma with potential clinical significance. J Exp Ther Oncol. 1996 ; 1: 13-22.